Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
A phase 3 trial (Randomized, double-blind, parallel assignment) in people with overweight or obesity. This page describes the trial as registered; it does not report results.
This is a registry entry describing a planned or ongoing trial. It is not a published result.
- Evidence type
- Trial registry record
- Status
- Completed
- Phase
- Phase 3
- Design
- Randomized, double-blind, parallel assignment
- Participants
- 2539
- Population
- Aged 18 years and over, with overweight or obesity.
- Intervention
- Tirzepatide, Placebo
- Primary outcome
- Percent Change From Baseline in Body Weight (Primary Treatment Period) (Baseline, Week 72)
- NCT: NCT04184622
Important limitations
This is a registry entry, not a published paper. It describes what the trial was designed to do and its current status, and has not been through peer review.
A trial's registered design does not tell you how well it was conducted, whether its results were reproduced, or how its findings apply outside the population it enrolled.
What this does NOT mean
A registered or completed trial is not evidence that a treatment works. Registration records intent and design; it says nothing about outcomes.
Nothing here indicates that any compound is approved, effective or appropriate for you. That is a conversation for you and your prescriber.
Sources
Educational summary of published research. Findings describe the study population, not you. Nothing here is a diagnosis, a dosing or titration recommendation, or advice to start, stop or change any treatment - those decisions belong with your prescriber.